These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4919553)

  • 21. [Clinical observations during accumulative oral glycoside therapy with meproscillarin (author's transl)].
    Pozenel H
    Arzneimittelforschung; 1978; 28(3a):560-2. PubMed ID: 348205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical and experimental studies on the effect of proscillaridin A].
    Grübl M; Klein K; Siedek H
    Wien Med Wochenschr; 1970 Jan; 120(4):51-5. PubMed ID: 5514084
    [No Abstract]   [Full Text] [Related]  

  • 23. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043.
    Uretsky BF; Valdes AM; Reddy PS
    Circulation; 1986 Mar; 73(3 Pt 2):III219-29. PubMed ID: 2935328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of neurotoxicity of cardiotonic glycosides.
    Gaitondé BB; Joglekar SN
    Br J Pharmacol; 1977 Feb; 59(2):223-9. PubMed ID: 13903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of the position of attachment of the lactone ring to the steroid nucleus on the action of cardiac glycosides.
    Mendez R; Pastelin G; Kabela E
    J Pharmacol Exp Ther; 1974 Jan; 188(1):189-97. PubMed ID: 4809267
    [No Abstract]   [Full Text] [Related]  

  • 26. [Report on the clinical test of peruvoside].
    Schwind K
    Med Welt; 1969 Jan; 3():134-42. PubMed ID: 5764799
    [No Abstract]   [Full Text] [Related]  

  • 27. [Modifying factors in carciac glycoside therapy].
    Krebs R
    Med Klin; 1976 Oct; 71(42):1759-70. PubMed ID: 790134
    [No Abstract]   [Full Text] [Related]  

  • 28. Peripheral haemodynamic effects of perindopril compared in patients with congestive heart failure and in normal volunteers.
    Thuillez C; Richard C; Richer C; Loueslati H; Perret L; Auzépy P; Giudicelli JF
    J Hypertens Suppl; 1988 Dec; 6(3):S41-3. PubMed ID: 2852235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinico-experimental characteristic of the new cardiac glycoside homphotin].
    Gatsura VV; Stupnitskiĭ AA
    Kardiologiia; 1968 Sep; 8(9):106-10. PubMed ID: 5728493
    [No Abstract]   [Full Text] [Related]  

  • 30. Haemodynamic effect of sublingual nifedipine in patients with congestive heart failure.
    Wasir HS; Sood AK
    Indian Heart J; 1984; 36(1):8-14. PubMed ID: 6706374
    [No Abstract]   [Full Text] [Related]  

  • 31. [Contribution to the konwledge of some effects of proscillaridin on the cardiovascular system. Electrocardiographic and radiocardiographic research].
    Sorrentino F; Musco A; Cascone O; Modica G
    Clin Ter; 1966 Jul; 38(1):39-48. PubMed ID: 5990470
    [No Abstract]   [Full Text] [Related]  

  • 32. [Principles and directives for practical treatment with cardiac glycosides].
    Dörffel EF
    Z Arztl Fortbild (Jena); 1971 Mar; 65(5):237-44. PubMed ID: 4997296
    [No Abstract]   [Full Text] [Related]  

  • 33. Contrasting effect on cardiac output of digoxin and gitoxin in humans during congestive heart failure.
    Col J; Wijns W; Brasseur L; Lesne M
    Int J Clin Pharmacol Ther Toxicol; 1981 Jul; 19(7):314-8. PubMed ID: 7263109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of combined treatment with hydantoinal and cardiac glycosides on the dynamics of left ventricular contraction].
    Adamska-Dyniewska H
    Pol Arch Med Wewn; 1969 Jul; 43(1):985-9. PubMed ID: 4898864
    [No Abstract]   [Full Text] [Related]  

  • 35. [Serum half-life and renal clearance of 3H peruvoside. Study on normal persons and patients with terminal kidney insufficiency].
    Kramer P; Willms B; Horenkamp J; Scheler F
    Verh Dtsch Ges Kreislaufforsch; 1969; 35():440-4. PubMed ID: 5380625
    [No Abstract]   [Full Text] [Related]  

  • 36. Glucagon in resistant heart-failure and cardiogenic shock.
    Wilcken DE; Lvoff R
    Lancet; 1970 Jun; 760(1):1315-8. PubMed ID: 4193948
    [No Abstract]   [Full Text] [Related]  

  • 37. [Clinical evaluation of the cardiotonic effects of proscilaridine].
    Netto MP; Forti N; Formicola A; Chryssovergis G; Zillioto EE; Campanari JC; Lunardi W; Giannini SD
    Rev Hosp Clin Fac Med Sao Paulo; 1973; 28(6):300-4. PubMed ID: 4767562
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of congestive heart failure with cardiac glycosides. I. New theses in the principles of treatment].
    Tomov I
    Vutr Boles; 1980; 19(6):7-14. PubMed ID: 7210653
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiovascular effects of glucagon in man.
    Parmley WW; Glick G; Sonnenblick EH
    N Engl J Med; 1968 Jul; 279(1):12-7. PubMed ID: 4872564
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical studies with a new cardiac glycoside proscillaridine A (Sandoscill)].
    Hansel J
    Med Klin; 1968 Jun; 63(23):919-22. PubMed ID: 4875202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.